Active metal microspheres, composite embolic agents based on active metal microspheres
The composite embolic agent with active metal microspheres or nanohydrides in iodine oil addresses the limitations of TAE/TACE and immunotherapy by modulating the tumor microenvironment, enhancing treatment efficacy through sustained hydrogen release and immune activation.
Patent Information
- Application Number
- JP2024527620
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-04-30
- Filing Date
- 2022-11-04
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2042-11-04
AI Technical Summary
Current treatments for liver cancer, such as transcatheter arterial embolization (TAE) and transcatheter chemoembolization (TACE), face challenges due to the heterogeneous vasculature of hepatocellular carcinoma (HCC), leading to incomplete tumor necrosis, recurrence, and metastasis, while immunotherapy is hindered by the complex tumor microenvironment (TME) that suppresses cytotoxic T lymphocytes (CTLs).
A composite embolic agent comprising active metal microspheres or nanohydrides dispersed in iodine oil, which releases hydrogen and hydroxide ions to modulate the tumor microenvironment, enhancing embolization therapy by neutralizing acidity and activating the immune system.
The composite embolic agent achieves sustained hydrogen release, improves tumor microenvironment, and amplifies the therapeutic effect of embolization therapy, offering improved treatment outcomes compared to iodine oil perfusion alone.
Smart Images

Figure 2024544938000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS The present invention belongs to the field of pharmaceutical technology, and particularly relates to an iodine oil-based active metal microsphere or nanohydride composite embolic agent and its preparation method and application.
[0002] The present invention relates to active metal microspheres, composite suppositories based on active metal microspheres, nanohydrides, composite suppositories based on nanohydrides, metal composite structures, and composite suppositories based on metal composite structures. [Background technology]
[0003] Cancer is one of the most dangerous diseases currently facing mankind, causing millions of deaths worldwide every year. In particular, liver cancer, among many cancers, is often difficult to cure by conventional antitumor treatments such as surgical resection, organ transplantation, radiation therapy, and chemotherapy due to its insidious onset, high malignancy, invasiveness, rapid proliferation, high recurrence rate, and high mortality rate. In recent years, tumor interventional therapy has attracted widespread attention due to its excellent therapeutic effect and few side effects. In particular, transcatheter arterial embolization (TAE), which efficiently delivers vascular embolic substances and chemotherapeutic agents to tumor-proximal arteries by superselective arterial perfusion, is one of the most effective methods of targeted drug delivery and is considered the standard treatment for some mid- to late-stage solid tumors. However, the high heterogeneity of HCC and its vasculature hinders the therapeutic response of HCC tissues with low blood supply, and after TAE / or combined with drugs (transcatheter chemoembolization, TACE), hypoxia-resistant HCC cells and tumor-derived stem cells (CSLCs) accumulate in large quantities in HCC lesions, leading to failure of TAE treatment. In addition, the hypoxic, weakly acidic, and immunosuppressive microenvironment caused by arterial embolization promotes the rapid proliferation, metastasis, and drug resistance of HCC cells, preventing the complete eradication of HCC. Therefore, TAE / TACE treatment is often accompanied by problems such as incomplete tumor necrosis, recurrence / metastasis, and low patient survival rate, greatly limiting its scope of application.
[0004] In recent years, immunotherapy, i.e., a therapy that fights cancer by activating the patient's immune system, has shown great potential in the field of tumor treatment. In immunotherapy, cytotoxic T lymphocytes (CTLs) play a key role in attacking tumor cells. However, the complex tumor microenvironment (TME), including vascular abnormalities, acidic pH, hypoxia, and high concentrations of reactive oxygen species (ROS), greatly restrict the activity and killing ability of CTLs within solid tumors. Meanwhile, the above physiological characteristics of the TME promote the infiltration of various immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs), tumor adenocarcinomas (TAMs), and regulatory T cells (Tregs), forming an immunosuppressive microenvironment. The immunosuppressive TME is one of the major barriers that significantly inhibits tumor immunotherapy. Therefore, modulating the TME through multiple pathways has been considered as an attractive strategy to improve the efficacy of various cancer treatments, especially tumor immunotherapy.
[0005] Hydrogen (H 2 ) is an endogenous gas that has important physiological / pathological regulatory functions. In the past decade, hydrogen has been shown to have important effects in both anti-inflammatory and anti-tumor areas due to its high biodiffusion ability. However, due to the low solubility of hydrogen, it is difficult to meet the dosage required for effective treatment with the currently mainstream hydrogen introduction methods such as oral hydrogen water, injectable hydrogen salts, and hydrogen inhalation therapy, and the development of novel hydrogen carriers and their introduction strategies is required. By reacting active metal (potassium, calcium, sodium, magnesium, aluminum, zinc, gallium, iron, manganese, tin, etc.) microspheres or metal hydride materials (calcium, magnesium, lithium, sodium, potassium, strontium, cerium hydride, etc.) with water, hydrogen is efficiently released and at the same time, hydrides are generated by the reaction, which neutralizes the acidic tumor microenvironment and activates the immune system, thereby achieving microenvironmental regulation by enhancing hydrogen-immune synergy. However, these active metals and metal hydrides are too active and unstable in aqueous systems, and some even explode when in direct contact with water, so they are generally considered difficult to use directly in tumor treatment. Summary of the Invention
[0006] In order to solve the above technical problems, the present invention provides a composite embolic agent and its preparation method and application. After the composite embolic agent provided by the present invention is delivered to liver cancer lesions by interventional procedures, the iodine oil is deposited in the liver cancer tissue to induce embolization therapy, the active metal or hydride releases hydrogen on site to induce hydrogen therapy, and the hydroxide ion is released to regulate the immune microenvironment, thereby amplifying the effect of embolization therapy.
[0007] In the present invention, magnesium microspheres or nano-calcium hydride are selected as the preparation to be examined, and dispersed in clinical iodine oil suppository, and the obtained composite embolic agent has excellent chemical stability, and even when mixed with aqueous solution, the reaction rate is slower, and hydrogen gas can be generated gently and continuously.When used in tumor interventional embolization therapy, the present invention obtains iodine oil microspheres or nano-calcium hydride composite embolic agent, which can generate hydrogen gas synchronously and continuously in tumor, so that the function of hydrogen therapy can be realized, and the tumor microenvironment can be improved by neutralizing the acidic environment of the tumor, and the therapeutic effect can be significantly improved compared with iodine oil perfusion alone.
[0008] The first object of the present invention is to provide an iodine oil-based metal microsphere or nano-hydride composite embolic agent, comprising active metal microspheres or nano-hydride material and iodine oil dispersion protection agent, the mass percentage of the active metal microspheres or nano-hydride material in the composite embolic agent is 0.1-10%, where the iodine oil is a medical embolic agent, in which the iodine oil has dispersion and protection functions, the iodine oil protects the active metal and hydride, and slows down the reaction rate with water, thereby realizing the sustained release of hydrogen and hydride, and fulfilling the function of long-term treatment.
[0009] In one embodiment of the present invention, the active metal microspheres have a size of 0.1 to 20 microns.
[0010] In one embodiment of the present invention, the active metal microspheres have a size between 20 and 500 microns.
[0011] In one embodiment of the invention, the active metal microspheres have a size of 0.1 microns or more, 5 microns or more, 10 microns or more, 20 microns or more, 50 microns or more, 100 microns or more, 150 microns or more, 200 microns or more, 250 microns or more, 300 microns or more, 350 microns or more, 400 microns or more, 450 microns or more, up to 500 microns.
[0012] In one embodiment of the present invention, the nano-hydride has a particle size of 5 to 200 nanometers.
[0013] In one embodiment of the present invention, 5 to 200 nm corresponds to 0.005 to 0.2 microns.
[0014] In one embodiment of the present invention, the nano hydride material has a particle size of 0.2 to 500 microns.
[0015] In one embodiment of the invention, the active metal microspheres have a size of 0.1 microns or more, 0.005 microns or more, 0.01 microns or more, 0.05 microns or more, 0.1 microns or more, 0.5 microns or more, 1 micron or more, 5 microns or more, 10 microns or more, 20 microns or more, 50 microns or more, 100 microns or more, 150 microns or more, 200 microns or more, 250 microns or more, 300 microns or more, 350 microns or more, 400 microns or more, 450 microns or more, up to 500 microns.
[0016] If the particle size of the microspheres is too large, they cannot be dispersed well in the dispersing agent and cannot be successfully applied in clinical practice.
[0017] In one embodiment of the present invention, the active metal microspheres are prepared by an aerosolization powdering method, that is, an active metal ingot is heated and melted, then atomized and cooled to obtain active metal microspheres.
[0018] In one embodiment of the present invention, the nano-hydride material is prepared by liquid phase exfoliation, that is, metal hydride is ultrasonically dispersed in an exfoliation solvent for 0.2-4 hours, and then centrifuged to obtain the nano-hydride material.
[0019] In one embodiment of the present invention, the ultrasonic power is 50-100W and the operating temperature is 10-20°C.
[0020] In one embodiment of the present invention, the ratio of the amount of the metal hydride to the amount of the stripping solvent (M 質量(mg) :V 体積(mL) ) is 0.1:1 to 10:1.
[0021] In one embodiment of the invention, the active metal is one or more of potassium, calcium, sodium, magnesium, aluminum, zinc, gallium, iron, manganese and tin.
[0022] In one embodiment of the invention, the metal hydride is one or more of calcium hydride, magnesium hydride, lithium hydride, sodium hydride, potassium hydride, strontium hydride, and cerium hydride.
[0023] In one embodiment of the present invention, the stripping solvent is one or more of N-methylpyrrolidone, dimethylsulfoxide or polyethylene glycol 200, pyrrole and N,N-dimethylformamide.
[0024] A second object of the present invention is to provide a method for preparing iodine oil-based active metal microspheres or nano hydride composite embolic agent, comprising the steps of mixing active metal microspheres or nano hydride materials with iodine oil and dispersing them uniformly by ultrasonic treatment to obtain the iodine oil-based active metal microspheres or nano hydride composite embolic agent.
[0025] The third object of the present invention is to provide the application of said iodine oil-based active metal microspheres or nano-hydride composite embolic agent in the preparation of an embolization therapeutic agent for liver cancer.
[0026] A fourth object of the present invention is to provide active metal microspheres, which have a stronger metal activity than hydrogen.
[0027] Furthermore, the active metal microspheres have a particle size of 0.1 to 500 microns.
[0028] Furthermore, the metal of the active metal microspheres is one or more selected from the group consisting of potassium, calcium, sodium, magnesium, aluminum, zinc, gallium, iron, manganese and tin.
[0029] Furthermore, the shape of the active metal microspheres may be spherical, mesoporous, sea urchin-like or polyhedral.
[0030] A fifth object of the present invention is to provide a composite embolic agent containing active metal microspheres.
[0031] Furthermore, the composite embolic agent further comprises a dispersing agent.
[0032] Furthermore, the mass ratio of the active metal microspheres to the dispersant is 0.1:100 to 50:100.
[0033] Additionally, the dispersant is an organic phase.
[0034] Furthermore, the dispersant is an oil phase.
[0035] Further, the dispersant is selected from one or more of iodine oil, poppy seed oil, soybean oil and olive oil.
[0036] A sixth object of the present invention is to provide a nano-hydride, said nano-hydride having a particle size of 0.005 to 1 micron.
[0037] Further, the nanohydrides are selected from one or more of calcium hydride, magnesium hydride, lithium hydride, sodium hydride, potassium hydride, strontium hydride and cerium hydride.
[0038] A seventh object of the present invention is to provide a composite embolic agent, said composite embolic agent comprising a nano hydride.
[0039] Additionally, the composite embolic agent further comprises a dispersing agent.
[0040] Furthermore, the mass ratio of the nano-hydride to the dispersant is 0.1:100 to 50:100.
[0041] Additionally, the dispersant is an organic phase.
[0042] Furthermore, the dispersant is an oil phase.
[0043] Further, the dispersant is selected from one or more of iodine oil, poppy seed oil, soybean oil and olive oil.
[0044] An eighth object of the present invention is to provide an anti-tumor preparation comprising active metal microspheres.
[0045] A ninth object of the present invention is to provide a tumor preparation comprising a composite embolic agent, said composite embolic agent comprising activated metal microspheres.
[0046] A tenth object of the present invention is to provide an oncology preparation comprising nanohydrides.
[0047] An eleventh object of the present invention is to provide a tumor preparation comprising a composite embolic agent, said composite embolic agent comprising said nanohydride.
[0048] A twelfth object of the present invention is to provide a metal composite structure, the metal composite structure comprising a core structure and a bonding layer bonded to a surface of the core structure, the core structure being a first metal and the bonding layer being a second metal, the first metal being an active metal different from the second metal.
[0049] Furthermore, the core structure has a spherical shape, a polyhedral shape, a porous structure, or a rod shape.
[0050] Furthermore, the first metal has a metal activity that is stronger than hydrogen activity, ie, the first metal reacts with water to produce hydrogen.
[0051] Further, the first metal is selected from at least one of potassium, calcium, sodium, magnesium, aluminum, zinc, gallium, iron, manganese, and tin.
[0052] Furthermore, the second metal has a metal activity that is less than the activity of hydrogen.
[0053] Furthermore, the second metal is selected from one or more of copper, silver, platinum and gold.
[0054] Furthermore, the metal composite structure has a minor axis of 0.1 to 500 microns.
[0055] Furthermore, the metal composite structure has a minor axis of 0.1 microns or more, 0.005 microns or more, 0.01 microns or more, 0.05 microns or more, 0.1 microns or more, 0.5 microns or more, 1 micron or more, 5 microns or more, 10 microns or more, 20 microns or more, 50 microns or more, and 100 microns or less, 150 microns or more, 200 microns or more, 250 microns or more, 300 microns or more, 350 microns or more, 400 microns or more, 450 microns or more, and 500 microns or less.
[0056] When the core structure of the metal composite structure has a spherical shape, the minor axis of the metal composite structure is the particle diameter.
[0057] Furthermore, the grain size of the metal composite structure is uniformly distributed.
[0058] A thirteenth object of the present invention is to provide a composite embolic agent, the composite embolic agent comprising the metal composite structure and a dispersing agent, the metal composite structure being dispersed in the dispersing agent.
[0059] Furthermore, the metal composite structures are uniformly dispersed in the dispersant.
[0060] Furthermore, the mass ratio of the metal composite structure to the dispersant is 0.1:100 to 50:100, that is, the mass fraction of the metal composite structure in the dispersant is 0.1% to 50%.
[0061] Furthermore, the mass fraction of the metal composite structure in the organic phase is 0.1% or more, 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, and 50% or less.
[0062] Additionally, the dispersant is an organic phase.
[0063] Further, the organic phase is an oil phase.
[0064] Furthermore, the oil phase is selected from at least one of iodine oil, poppy seed oil, soybean oil, olive oil.
[0065] A fourteenth object of the present invention is to provide a method for preparing a metal composite structure comprising the step of bonding said second metal to a surface of said first metal.
[0066] Additionally, physical or chemical methods may be used to bond the second metal to the surface of the first metal.
[0067] Further, said chemical methods are selected from substitution methods.
[0068] The substitution method further comprises subjecting the first metal to a solution containing ions of a higher valence state of the second metal.
[0069] Furthermore, the solution containing the high valent ions of the second metal contains one or more of chloroaurate ions, chloroplatinate ions, copper ions and silver ions. In the method for preparing the metal composite structure, the efficiency of the metal substitution can be promoted by shaking, ultrasonic waves, or the like.
[0070] Moreover, the physical method is a mechanical stirring method.
[0071] Specifically, the mechanical stirring method comprises mixing and stirring the second metal in a solid state and the first metal in a liquid state.
[0072] Additionally, the physical method may be a vapor deposition method.
[0073] A fifteenth object of the present invention is to provide a method for preparing a composite embolic agent, which comprises a step of dispersing the metal composite structure in the dispersing agent.
[0074] Furthermore, the method for preparing the composite embolic agent of the present invention further comprises an ultrasonic dispersion step.
[0075] A sixteenth object of the present invention is to provide an alloy metal particle, the alloy metal particle comprising at least two metals having different activities, the two metals having different activities being mixed in an alloy state.
[0076] Further, the alloying metal particles include at least one active metal monomer and at least one inactive metal monomer, the active metal monomer being alloyingly mixed with the inactive metal monomer.
[0077] Additionally, the active metal monomer has a metal activity greater than its hydrogen activity.
[0078] Further, the active metal monomer is selected from one or more of potassium, calcium, sodium, magnesium, aluminum, zinc, gallium, iron, manganese and tin.
[0079] Additionally, the inert metal monomer has a metal activity that is less than the hydrogen activity.
[0080] Further, the inert metal monomer is selected from at least one of copper, silver, platinum and gold.
[0081] Furthermore, the alloying metal particles have a spherical shape, a polyhedral shape, a porous structure, a sea urchin shape, or a rod shape.
[0082] Furthermore, the alloy metal particles have a minor axis size of 0.1 to 500 microns.
[0083] Further, the alloy metal particles have a minor axis diameter of 0.1 microns or more, 0.005 microns or more, 0.01 microns or more, 0.05 microns or more, 0.1 microns or more, 0.5 microns or more, 1 micron or more, 5 microns or more, 10 microns or more, 20 microns or more, 50 microns or more, up to 100 microns, 150 microns or more, 200 microns or more, 250 microns or more, 300 microns or more, 350 microns or more, 400 microns or more, 450 microns or more, up to 500 microns.
[0084] When the alloying metal particles are spherical, the minor axis of the alloying metal particles is the particle diameter.
[0085] Here, the alloying metal nanoparticles can be commercially purchased or can be prepared by an existing alloy preparation method.
[0086] A seventeenth object of the present invention is to provide a composite embolic agent comprising said alloying metal particles and a dispersing agent, wherein said alloying metal particles are dispersed in said dispersing agent.
[0087] Furthermore, the alloy metal particles are uniformly dispersed in the dispersant.
[0088] Additionally, the dispersant is an organic phase.
[0089] Further, the organic phase is an oil phase.
[0090] Furthermore, the oil phase is one or more selected from iodine oil, poppy seed oil, soybean oil and olive oil.
[0091] Furthermore, the mass fraction of the alloy metal particles in the dispersant is 0.1% to 50%.
[0092] An eighteenth object of the present invention is to provide a method for preparing a composite embolic agent comprising the step of mixing said alloying metal particles with said dispersing agent.
[0093] Furthermore, the preparation method further comprises an ultrasonic dispersion step.
[0094] A nineteenth object of the present invention is to provide a method for treating tumors using a composite embolic agent comprising a metal composite structure for tumor embolization therapy.
[0095] A twentieth object of the present invention is to provide a method for treating tumors using a composite embolic agent containing alloy metal particles for tumor embolization therapy.
[0096] The inventors have experimentally confirmed that metal microspheres, nanohydrides, metal composite structures, and alloy metal particles cannot be effectively dispersed when their mass fraction in a dispersant exceeds 50%, making catheter injection for practical use difficult.
[0097] A twenty-first object of the present invention is to provide a method for tumor therapy using a composite embolic agent containing metal microspheres for the treatment of liver cancer, kidney cancer, pancreatic cancer, lung cancer, and pelvic malignant tumors.
[0098] A twenty-second object of the present invention is to provide a method for treating tumors using a composite embolic agent containing a metal composite structure for treating liver cancer, kidney cancer, pancreatic cancer, lung cancer, and pelvic malignant tumors.
[0099] The twenty-third object of the present invention is to provide a tumor treatment method using a composite embolic agent containing alloy metal particles for the treatment of liver cancer, kidney cancer, pancreatic cancer, lung cancer, and pelvic malignant tumors.
[0100] A twenty-fourth object of the present invention is to provide a tumor treatment kit comprising a composite embolic agent comprising metal microspheres, metal composite structures or alloy metal particles.
[0101] Compared with the prior art, the beneficial effects of the above technical solutions provided by the present invention include, but are not limited to, the following:
[0102] The present invention provides a composite embolic agent and a preparation method thereof, in which active metal microspheres or nano hydride are dispersed in an embolic agent of iodine oil in different proportions, and the obtained composite embolic agent has excellent chemical stability. Even when mixed with an aqueous solution, the reaction rate is slower, hydrogen can be generated gently and continuously, and the problem of the violent reaction between active metal microspheres or nano hydride materials and water cannot be controlled can be solved. In the present invention, the embolic agent of iodine oil microspheres or nano metal hydride is locally administered to the liver cancer tissue through an interventional procedure, and iodine oil is deposited in the liver cancer tissue to perform embolic therapy, so that the active metal microspheres or nano metal hydride continuously generate hydrogen in the tumor, thereby achieving the function of hydrogen therapy. At the same time, the released hydride can neutralize the weak acidic microenvironment of the tumor to improve the tumor microenvironment, amplify the effect of embolic therapy, and significantly enhance the therapeutic effect compared with only iodine oil perfusion.
[0103] In this invention, magnesium microspheres or nano calcium hydride were selected as the preparations to be investigated and dispersed in clinical suppository iodine oil, and the obtained composite preparations have good chemical stability.
[0104] Due to the active metal composite structure or alloy metal particles, the active metal microspheres with large particle size have a high reaction efficiency, and the composite embolic agent combined with iodine oil can significantly improve the tumor microenvironment and improve the effect of embolic therapy. Selecting different metals to prepare the metal composite structure or alloy particles has additional effects such as improving the immune microenvironment and improving the retention. By using the active metal composite structure or alloy metal particles mixed with a dispersing agent in embolic therapy, embolic therapy and hydrogen therapy can be combined, which can greatly improve the effect of embolic therapy and at the same time solve the problem that active metals are unstable under physiological environment and improve the safety of active metals in tumor treatment. The composite embolic agent described in the present invention is easy to prepare and easy to use clinically. [Brief description of the drawings]
[0105] In order to make the present invention easier to understand clearly, the present invention will be described in more detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings. [Figure 1] 1 is a micrograph of the magnesium metal microspheres obtained in Example 1 of the present invention. [Diagram 2] 4 is a photograph showing hydrogen release evaluation in different buffer solutions of the metallic magnesium microspheres obtained in Example 1 of the present invention. [Diagram 3] 1 is a transmission electron microscope (TEM) photograph of calcium hydride nanoparticles obtained in Example 2 of the present invention. [Figure 4] FIG. 2 is an X-ray diffraction diagram (XRD) of calcium hydride nanoparticles obtained in Example 2 of the present invention. [Diagram 5] 1 is an optical photograph of the magnesium metal microsphere-iodine oil composite embolic agent obtained in Example 1 of the present invention. [Figure 6] 2 is an optical photograph of the nano-calcium hydride-iodine oil composite embolic agent obtained in embodiment 2 of the present invention. [Figure 7] 1 shows an evaluation of hydrogen release from the calcium hydride-iodine oil composite bolus preparation obtained in Example 2 of the present invention. [Figure 8]FIG. 2 is a schematic diagram of an interventional procedure for rabbit liver cancer in Application Example 1 of the present invention. [Figure 9] 1 shows DSA images of liver cancer lesions during an interventional procedure in a rabbit in Application Example 1 of the present invention. [Figure 10] 1 shows CT images of liver cancer lesions before and after embolization with the magnesium microsphere-iodine oil composite embolic agent obtained in Application Example 1 of the present invention in a rabbit. [Figure 11] 13 shows CT images of liver cancer lesions in a rabbit before and after embolization using the nano-calcium hydride-iodine oil composite embolic agent obtained in the second embodiment of the present invention. [Figure 12] 18F-FDG PET images of liver cancer lesions before and after embolization in a rabbit using the nano-calcium hydroxide-iodine oil composite embolic agent obtained in embodiment 2 of the present invention. [Figure 13] 18F-FDG intensity of liver cancer lesions before and after embolization in a rabbit using the nano-calcium hydride-iodine oil composite embolic agent obtained in embodiment 2 of the present invention. [Figure 14] 1 shows an immunohistochemical analysis of isolated liver cancer lesions 7 days after rabbit embolization using the nano-calcium hydride-iodine oil composite embolic agent obtained in embodiment 2 of the present invention. [Figure 15] 13 shows the apoptosis level in a solitary focus of hepatocellular carcinoma 7 days after embolization of rabbits using the nano-calcium hydride-iodine oil composite embolic agent obtained in embodiment 2 of the present invention. [Figure 16] 1 shows the proliferation activity in a solitary focus of hepatocellular carcinoma 7 days after embolization of a rabbit using the nano-calcium hydride-iodine oil composite embolic agent obtained in embodiment 2 of the present invention. [Figure 17] 1 is a particle size distribution of the magnesium-platinum metal composite structure described in Example 3 of the present invention. [Figure 18] 1 is a graph of hydrogen yield statistics in 96% ethanol solution of magnesium microspheres tested in Example 4 and Mg@Pt composite structure obtained in Example 3 of the present invention. [Figure 19]FIG. 13 is a graph showing the tumor growth curve of mice statistically obtained in Example 6 of the present invention using the Mg@Pt metal composite structure-iodine oil composite embolization therapy prepared in Example 3 for tumor treatment in mice. [Figure 20] FIG. 11 is a scanning electron microscope image of raw magnesium microspheres and Mg@Pt composite structure in Example 7 of the present invention. [Figure 21] 1 is an XRD powder diffraction spectrum of the magnesium-platinum metal composite structure prepared in Example 8 of the present invention. [Figure 22] 9 is a graph showing the measurement of total hydrogen generation in a phosphate buffer solution for the Mg@platinum metal composite structure prepared by testing in Example 8 in the present invention. [Diagram 23] 1 is a statistical graph of particle size distribution of large magnesium microspheres in Example 15 of the present invention. [Figure 24] 14 is a graph showing the total hydrogen generation determination curve when the magnesium microspheres in Example 15 of the present invention are put into buffer solutions under different pH conditions and detected by gas chromatography in Example 16 of the present invention. [Diagram 25] 2 is a graph showing the particle size distribution of magnesium microspheres in Example 18 of the present invention. [Figure 26] 13 is a graph of the amount of hydrogen produced by magnesium microspheres in buffers of different pH as a function of time in Example 18 of the present invention. [Figure 27] 14 shows detection images of a rabbit liver cancer model after establishment of the rabbit liver cancer model in Example 19 and after application of a composite embolic agent to the rabbit liver cancer model. The image on the left is a detection image of a rabbit liver cancer model in Example 19 after establishment of the rabbit liver cancer model, and the image on the right is a detection image of a rabbit liver cancer model exhibiting vascular embolism after application of a composite embolic agent to the rabbit liver cancer model. [Figure 28] 13 shows ultrasound images before and after delivery of magnesium microspheres to the lesion site in Example 19 of the present invention. [Figure 29] CT image data at various times before and after treatment in Example 19.1 of the present invention and corresponding Example 19.2. [Diagram 30] 1 is an X-ray diffraction pattern of a manganese-platinum metal composite structure of the present invention. [Diagram 31] 1 is a statistical graph of hydrogen production content of the manganese metal and metal composite structure of the present invention at different time points in phosphate buffer solution. [Diagram 32] 1 shows the tumor growth curves of different groups of mice in Example 22 of the present invention. [Diagram 33] 2 is a statistical graph showing the residual magnesium amount at different time points in the tumor site of mice after intratumoral injection of magnesium microsphere-iodine oil composite embolic agent in Example 23 of the present invention. [Diagram 34] 1 is a graph showing the time course of intratumoral pH in mice in Example 24 of the present invention. [Diagram 35] 13 is a graph showing the statistics of hydrogen amount produced by magnesium-platinum metal composite structures with different ratios in solution for 24 hours in Example 25 of the present invention; [Diagram 36] 2 is a graph showing the statistics of the amount of hydrogen produced by different ratios of manganese-platinum metal composite structures in solution for 24 hours in Example 26 of the present invention; DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0106] The present invention will now be further described in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand and practice the present invention, but the cited embodiments should not be construed as limiting the present invention.
[0107] In order to more specifically express the technical solutions of the above invention, specific embodiments are given below to demonstrate the technical effects, but it should be emphasized that these embodiments are for illustrating the present invention, and do not limit the scope of the present invention.
[0108] As used herein and in the claims, the terms "a," "one," "a kind," and / or "the" do not specifically refer to the singular and may include the plural, unless the context clearly suggests otherwise. The terms "comprising" and "comprising" are merely intended to imply the inclusion of the specifically identified elements and do not constitute an exclusive list, and the device may include other elements. The term "one embodiment" means "at least one embodiment," and the term "another embodiment" means "at least one other embodiment." Relevant definitions of other terms are provided in the following description.
[0109] The test apparatus and test method used in the embodiments of this specification are as follows. Morphological characterization: transmission electron microscope (FEI Tecnai F20 TEM), scanning electron microscope (ZEISS Sigma); Elemental analysis: Powder X-ray diffractometer (PANalytical X-ray diffractometer); Hydrogen production efficiency measurement: Gas chromatograph (SIEMENS MAXUM II); In vivo angiography to detect embolism: DAS digital subtraction angiography (PHILIPS FD20); In vivo angiography to detect tumor size: (1) CT (PHILIPS Access CT): Evaluation of treatment outcomes using CT imaging with Optiray contrast agent; (2) PET-CT (GEMINI TF PET / CT): Using positron emission tomography (PET) / CT images as a nuclide probe 18 To evaluate the efficacy of F-FDG-based interventional embolization.
[0110] Methods for evaluating tumor apoptosis and proliferation: Through tumor sections stained with fluorescently labeled TUNEL or Ki67 proteins, observe the percentage of TUNEL-positive cells or Ki67-positive cells relative to tumor cells in the field of view, and count them as the apoptosis rate or added value of tumor cells.
[0111] The tumor cell line in this embodiment is the H22 tumor cell line.
[0112] The present invention provides a composite embolic agent comprising active metal microspheres or nanohydride materials and an iodine oil dispersion protectant.
[0113] Here, the active metal microspheres are one or more of potassium, calcium, sodium, magnesium, aluminum, zinc, gallium, iron, manganese and tin. The active metal microspheres are micron-sized and have a particle size of 0.1 to 20 microns. The active metal microspheres are prepared from active metal ingots by an aerosol powder method. The hydride is one or more of cationic metal hydrides such as calcium hydride, magnesium hydride, lithium hydride, sodium hydride, potassium hydride, strontium hydride, and cerium hydride.
[0114] The above hydrides are all nano-sized, with a particle size of 5 to 200 nm. The nano-hydride raw material is obtained by exfoliating the hydride raw material using a liquid-phase exfoliation solvent method, and the specific reaction conditions are to disperse the metal hydride raw material in the exfoliation solvent N-methylpyrrolidone, exfoliate it ultrasonically for 20 minutes, and obtain the nano-hydride product by ultracentrifugation.
[0115] Then, the active metal microspheres or nano hydride particles are mixed with iodine oil and uniformly dispersed by ultrasonic waves to obtain a composite embolic agent, and the mass% content of the active metal microspheres or nano hydride in the composite embolic agent is 0.1-10%. The composite embolic agent obtained by the preparation is locally delivered to liver cancer tissue by interventional procedures, the iodine oil is deposited in the liver cancer tissue to cause embolic therapy, the active metal microspheres or hydride release hydrogen on the spot to induce hydrogen therapy, and the release of the active metal microspheres or hydride regulates the tumor microenvironment to further amplify the embolic therapy effect. The composite embolic agent described in the present invention regulates the tumor microenvironment by releasing hydrogen and hydroxide on the spot using the active metal or metal hydride, and shows a composite embolic therapy effect superior to embolic therapy using iodine oil alone.
[0116] Example 1: Preparation of magnesium microsphere-iodine oil composite embolic agent A magnesium metal ingot was placed in an aerosol powder manufacturing device, and the magnesium ingot was heated to 700°C to become a stable, fluid liquid. The liquid magnesium was then atomized and cooled at high speed with an inert gas argon at a gas flow speed of 2 to 2.5 Mach to obtain magnesium powder, which was then passed through a 1000 mesh sieve to obtain 10 micron magnesium microspheres. The structure of the obtained magnesium microspheres was analyzed, and the results are shown in Figures 1 and 2.
[0117] The magnesium microspheres prepared above were dispersed in a commercially available iodine oil composite embolic agent at a mass fraction of 1% of the magnesium microspheres, and then ultrasonically dispersed or shaken to obtain a magnesium microsphere-iodine oil composite embolic agent. If desired, the composite embolic agent can be customized so that the mass ratio of the magnesium microspheres is in the range of 1%. The commercially available iodine oil used as the dispersant is a light yellow, clear, transparent liquid, and the prepared microsphere magnesium-iodine oil composite embolic agent is a blackish yellow liquid, and its optical photograph is shown in Figure 5.
[0118] FIG. 1 is a micrograph of the prepared magnesium microspheres, which shows that the particle size is about 10 microns and the morphology is uniform.
[0119] Figure 2 shows the rate of hydrogen release from magnesium microspheres in buffer solutions with different pH values (7.4, 6.4, and 5.5). It can be seen that the higher the acidity of the solution, the greater the amount of bubbles generated and the faster the hydrogen release rate.
[0120] Example 2: Preparation of calcium hydride-iodine oil composite embolic agent Calcium hydride powder and the organic solvent N-methylpyrrolidone were placed in a reactor, and the ratio of calcium hydride powder to N-methylpyrrolidone (M 質量(mg) :V 体積(mL) ) was set to 10:1. The calcium hydride powder was uniformly dispersed in N-methylpyrrolidone by vigorous vibration. The mixed dispersion was placed in an ultrasonic cleaner and ultrasonically treated for 0.3 hours. The ultrasonic cleaner had an output of 100 W and an operating temperature of 15°C. The treated reaction system was ultracentrifuged to remove the precipitate, which was then washed several times with ethanol to obtain calcium hydride nanoparticles. The structure of the obtained calcium hydride nanoparticles was analyzed, and the results are shown in Figures 3 and 4.
[0121] Among these, Figure 3 is a transmission electron micrograph of the prepared calcium hydride nanoparticles, which shows that the particle size of the preparation is about 7.9 nm and the morphology is uniform in size.
[0122] Figure 4 shows the X-ray diffraction spectrum of the synthesized nano-calcium hydride, where the abscissa is the degree of 2θ angle and the ordinate is the intensity. The 2θ angles of the characteristic diffraction peaks of calcium hydride nanoparticles are 28.18, 30.38, 32.04, 41.72, and 47.56, which correspond to the (011), (102), (111), (211), and (013) diffraction crystal planes, respectively. The above diffraction peak data are consistent with the standard X-ray diffraction data of calcium hydride (JCPDS no. 31-0266). This proves that calcium hydride nanoparticles can be prepared by the synthesis method described in this invention.
[0123] The nano calcium hydride powder prepared as above can be dispersed in a commercially available iodine oil composite embolic agent at 0.4% by mass, and then ultrasonicated or shaken to obtain a calcium hydride-iodine oil composite embolic agent. The composite embolic agent can be personalized according to requirements, and the mass ratio of nano calcium hydride powder is in the range of 0.4%. The commercially available iodine oil, which is the dispersant used, is a light yellow, clear, transparent liquid, as shown in the optical photograph in Figure 6 (left), and the prepared nano calcium hydride-iodine oil composite embolic agent is a milky white liquid, as shown in the optical photograph in Figure 6 (right).
[0124] Test Example: The hydrogen release properties of the nano-calcium hydride-iodine oil composite embolic agent obtained in Example 2 were tested. 50 microliters of the composite embolic agent was added dropwise to an EP tube containing 3 ml of water, and the generation of hydrogen gas was monitored in real time. As shown in the optical photograph in Figure 7, many bubbles were generated in the EP tube, indicating that the nano-calcium hydride-iodine oil composite embolic agent had good in-situ hydrogen release performance, and the stability and practicality of the composite embolic agent were confirmed.
[0125] Application Example 1: Interventional embolization therapy for rabbit hepatocellular carcinoma using the magnesium microsphere-iodine oil composite embolic agent obtained in Example 1 With the aid of CT image guidance, VX2 hepatocellular carcinoma tissue was directly embedded in the left lobe of the liver, and tumors were allowed to form after 2 weeks, obtaining an in situ rabbit hepatocellular carcinoma tumor model. The hormone-treated rabbits were randomly divided into three groups: (1) control group, (2) iodine oil group, and (3) magnesium microsphere-iodine oil composite embolic agent group. The detailed treatment plan is shown in Figure 8. Using a 2.0-F microcatheter and a trocar with a coaxial guidewire, the left hepatic artery containing the tumor lesion was accessed from the femoral artery under DSA fluoroscopy. Then, 0.3 ml of iodine oil or magnesium microsphere-iodine oil composite embolic agent was slowly injected into the left hepatic artery from the microcatheter while avoiding reflux. After surgery, the therapeutic effect was monitored by CT images and weighted CT. While iodine oil was deposited in the liver cancer lesion, magnesium microspheres were delivered locally to the lesion, where they slowly reacted with water to release hydrogen and magnesium hydroxide into the liver tumor, neutralizing the weakly acidic tumor microenvironment, and the hydrogen served as a trigger for hydrogen therapy. The combination of the two could enhance the efficacy of iodine oil embolization therapy.
[0126] Specific experimental results are shown in Figures 9 and 10. First, as shown in Figure 9, the size of the hepatocellular carcinoma lesion in the left lobe of the liver of the hormone-administered rabbit was 1.0-1.5 cm, indicating that the hepatocellular carcinoma model was successfully established. After femoral artery interventional procedure, it was confirmed that a large amount of iodine oil was deposited in the liver tumor area of the rabbits in the iodine oil group and the magnesium microsphere-iodine oil composite embolic agent group, indicating that the interventional embolization procedure was very successful. One week after the interventional procedure, the present invention evaluated the therapeutic effect using CT images combined with Optiray contrast agent. As a result, as shown in Figure 10, the tumor in the control group rapidly increased in volume by 3.3 times, and the CT signal intensity of the lesion area was 26.68 in the CT subtraction image, and it was evaluated as a progressive disease according to the Metropolitan Regression Indication Standard (mRECIST). In the iodine oil embolization alone group, tumor growth was inhibited and no increase in volume was observed, but some tissues of the lesion were still enhanced in the weighted CT image (the lesion was still partially enhanced in white in the CT subtraction image, and its CT signal intensity was 3.63), indicating that complete tumor killing could not be achieved with this dose of iodine oil embolization alone, and mRECIST evaluated it as partial remission. However, in the present invention, in the magnesium microsphere-iodine oil composite embolic agent administration group, no enhancement was observed at the tumor site (no white enhancement of the lesion was observed in the CT subtraction, and its CT signal intensity was 0.86), indicating that the composite embolic agent has a good therapeutic effect, and mRECIST evaluated it as complete remission.
[0127] Application Example 2: The calcium hydride-iodine oil composite embolic agent obtained in Example 2 in interventional embolization therapy for rabbit hepatocellular carcinoma In a similar modeling scheme as above, with the aid of CT image guidance, VX2 hepatocellular carcinoma tissue was directly embedded in the left lobe of the liver, and tumors were allowed to form after 2 weeks to obtain a rabbit hepatocellular carcinoma tumor in situ model. Tumor-bearing rabbits were randomly divided into three groups: (1) control group, (2) iodine oil group, and (3) nano-calcium hydride-iodine oil composite embolic agent group. Then, under DSA fluoroscopy, a 2.0-F microcatheter and a trocar with a coaxial guidewire were used to access the left hepatic artery containing the tumor focus from the femoral artery. Then, 0.3 ml of iodine oil or nano-calcium hydride-iodine oil composite embolic agent was slowly injected into the left hepatic artery through the microcatheter while avoiding backflow. After surgery, the therapeutic effect was monitored by CT images.
[0128] The size of the hepatocellular carcinoma lesion in the left lobe of the liver of the rabbits with tumors was 1.0-1.5 cm. After the interventional procedure, it was confirmed that a large amount of iodine oil was deposited in the liver tumor area of the rabbits in the iodine oil administration group and the nano calcium hydride-iodine oil composite embolic agent administration group, indicating that the interventional embolization procedure was very successful. One week after the interventional procedure, the present invention evaluated the therapeutic effect using CT images combined with Optiray contrast agents. The results are shown in Figure 11. The tumor in the control group rapidly grew, the volume increased 10 times, and the CT signal intensity of the lesion area was 21.46 in the CT subtraction image, and the mRECIST evaluated it as disease progression. In the iodine oil embolization alone group, tumor growth was suppressed and no increase in volume was observed, but some tissues of the lesion were still enhanced in the weighted CT image (CT subtraction showed that the lesion was still partially enhanced in white, with a CT signal intensity of 3.86), indicating that complete tumor killing could not be achieved with this dose by iodine oil embolization alone, and mRECIST evaluated it as partial remission. However, in the present invention, in the group administered with nano-hydrogen calcium-iodine oil composite embolic agent, no enhancement was observed at the tumor site (CT subtraction showed no white enhancement of the lesion, with a CT signal intensity of 1.35), so the composite embolic agent showed a good therapeutic effect and was evaluated as complete remission by mRECIST.
[0129] Since glucose transporter protein-3 is overexpressed on the surface of tumor cells, fluorinated glucose significantly accumulates in tumor tissues, which is a powerful clinical diagnosis for tumors. 18 F-FDG was used as a nuclide probe to evaluate the efficacy of interventional embolization therapy using positron emission tomography (PET) / CT imaging. As shown in Figures 12 and 13, the preoperative hepatocellular carcinoma lesions were 0.1 mm in diameter, 0.1 mm in diameter, and 0.2 mm in diameter. 18 Strong F strength of 6.95 18 On the 7th day after surgery, the tumor volume and hypermetabolic area in the untreated control group increased, and the mean 18 The F intensity increased to 9.64. On the other hand, in the iodine oil only group, 18 F-FDG signal was significantly decreased, with the mean 18 The F intensity was reduced to 5.26, but still at a mid-level. Of note, the nano-calcium hydride-iodine oil composite embolic agent group showed a significant improvement in the hepatocellular carcinoma site. 18 F-FDG signal disappeared completely, and the average 18 The F intensity was 2.40, which was not different from that of normal tissue (average of normal tissue 18 The F intensity was 2.20, confirming that the nano-calcium hydride-iodine oil composite embolic agent had the optimal combined therapeutic effect. Through the deposition of iodine oil, nano-calcium hydride was delivered to the tumor site in situ, and the interventional embolization therapy effect was enhanced by the in situ sustained release of hydrogen and calcium hydroxide, suggesting that the nano-calcium hydride-iodine oil composite embolic agent is an embolic agent with translational potential.
[0130] To further confirm the effect of embolic therapy, in the present invention, liver cancer tissue was isolated, and the tissue sections were stained with H&E, TUNEL, and Ki67, and histopathological analysis was performed to evaluate the damage, apoptosis, and cell proliferation of the tumor tissue. As shown in Figure 14, the group administered with the nano-calcium hydride-iodine oil composite embolic agent had the highest apoptosis rate of tumor cells (control group: 2.1%, iodine oil alone group: 62.7%, nano-calcium hydride-iodine oil composite embolic agent group: 87.6%) and the lowest cell proliferation rate (control group: 87.5%, iodine oil alone group: 26.1%); nano-calcium hydride-iodine oil composite suppository group: 2.9%) (Figures 15 and 16), confirming that this composite embolic agent has excellent therapeutic effects as a new embolic agent and is a drug that is expected to be used in clinical applications.
[0131] Example 3: Magnesium-Platinum Metal Composite Structure (Mg@Pt Composite Structure) Magnesium-platinum metal composite structure consisting of magnesium core structure and platinum particles bonded to the surface of the magnesium core structure, FIG. 17 shows the particle size distribution of the magnesium-platinum metal composite structure, the particle size distribution of the magnesium-platinum metal composite microspheres is about 25 μm, the magnesium-platinum metal composite structure is prepared as follows:
[0132] A 0.1% chloroplatinic acid ethanol solution was prepared, 100 mg of magnesium microspheres (particle size 24 microns) were added to the above chloroplatinic acid ethanol solution, and after ultrasonic treatment, the original gray-white magnesium microspheres were observed to change to black-brown. When the ethanol was completely evaporated, a magnesium-platinum metal composite structure (Mg@Pt composite structure) was obtained.
[0133] The number, shape and size of the magnesium core structure particles were matched to the corresponding chloroplatinic acid concentration.
[0134] Example 4: Examination of hydrogen generation rate from the magnesium-platinum metal composite structure of Example 3 In order to facilitate the comparison of the hydrogen generation efficiency between the magnesium microspheres and the magnesium-platinum metal composite structure, 20 mg of each of the magnesium microspheres and the magnesium-platinum metal composite structure obtained in Example 3 were weighed out and placed in a 96% ethanol solution to observe the generation of hydrogen in both samples, and hydrogen bubbles were observed during the reaction for about 10 seconds. As a result, as shown in FIG. 18, many bubbles of the magnesium-platinum metal composite structure appeared in the ethanol solution. When the number of bubbles generated in the same time was counted, it was found that the gas generation efficiency of the magnesium-platinum metal composite structure in the ethanol solution was about 200 times that of simple Mg microspheres, and the hydrogen generation efficiency of the magnesium-platinum metal composite structure was much greater than that of Mg microspheres, and was higher than that of active metal monomers. This is because in the magnesium-platinum metal composite structure, a protocell composite structure was formed between platinum, which is an inactive metal, and magnesium, which is an active metal, and the hydrogen generation efficiency of magnesium, which is an active metal, was increased.
[0135] Hydrogen is a highly cytotoxic oxygen radical, which is a hydroxyl radical (-OH) and a peroxynitrite anion (ONOO). - )], disrupting the intracellular redox balance and inducing apoptosis in tumor cells, while retaining reactive oxygen, which is physiologically necessary for normal cell signaling, with low toxicity and side effects. Therefore, the magnesium-platinum metal composite structure has a high hydrogen generation efficiency and contributes to increasing the hydrogen content in the tumor microenvironment, so it can regulate the tumor microenvironment more effectively, and the composite embolic agent prepared using this magnesium-platinum metal composite structure is believed to have a better therapeutic effect on tumors.
[0136] Example 5: Composite embolic agent This is a composite embolic agent consisting of the magnesium-platinum metal composite structure of Example 3 and iodine oil. Iodine oil alone has the appearance of a pale yellow, clear, transparent liquid, while the composite embolic agent is a milky white liquid, and the composite embolic agent was prepared by the following method. The magnesium-platinum metal composite structure prepared in Example 3 was dispersed in iodine oil (commercially available product) and uniformly dispersed by ultrasonic treatment or shaking to obtain a magnesium-platinum metal composite structure-iodine oil composite embolic agent, and the mass fraction of the magnesium-platinum metal composite structure in the iodine oil was 6.0%.
[0137] Example 6: Composite embolic agent for treating mouse tumors The magnesium-platinum metal composite structure-iodine oil composite embolic agent prepared in Example 5 was used to treat tumors in mice. First, H22 tumor cells were inoculated into the right hindquarters of the mouse to establish a subcutaneous liver cancer tumor model in the mouse. The tumors in the mouse were approximately 80 mm 3 When the mice reached the age of 18, they were randomly divided into two groups and administered iodine oil embolization therapy or magnesium-platinum metal composite structure-iodine oil composite embolization therapy, respectively. The tumor growth of the mice was measured and recorded, and a tumor growth curve was created.
[0138] Comparative Example 1: Iodine oil embolization agent for treating mouse tumors Comparative Example 1 differs from Example 6 in that the mice were treated with iodine oil embolization therapy, and the tumor growth of the mice was measured and recorded, while the treatment and test methods were the same as those of Example 6.
[0139] The results are shown in Figure 19. In Example 6, mice were treated with a Mg@Pt metal composite structure-iodine oil composite embolic agent, and the average tumor volume of the mice on the 10th day after treatment was approximately 50 cubic millimeters, whereas in Comparative Example 1, mice were treated with an iodine oil embolic agent, and the average tumor volume of the mice on the 10th day was nearly 400 cubic millimeters.
[0140] Thus, the therapeutic effect of the Mg@Pt metal composite structure-iodine oil composite embolic agent of Example 6 on tumors is significantly increased compared to the comparative ratio 1. *** in FIG. 19 means a statistically significant p-value <0.001, where the p-value represents a significant difference, and the smaller the p-value, the more significant the difference between the groups. The p-value calculated in this specification shows a significant difference between Example 6 and Comparative Example 1 compared to Example 6, indicating that the Mg@Pt metal composite structure-iodine oil composite embolic agent has a significantly improved tumor embolization therapeutic effect compared to the conventional iodine oil embolic agent.
[0141] Example 7: Magnesium-platinum metal composite structure and its preparation method A magnesium-platinum metal composite structure comprising a magnesium core structure and platinum particles bonded to the surface of the magnesium core structure, the core structure being spherical, and the magnesium-platinum metal composite microspheres having a particle size distribution of about 350 microns. The magnesium-platinum metal composite structure was prepared as follows. A 0.1% ethanol solution of chloroplatinic acid was prepared, and 100 mg of magnesium microspheres (particle size approximately 350 microns) were added to the above ethanol solution of chloroplatinic acid. When ultrasonic treatment was performed, it was confirmed that the magnesium microspheres, which were originally grayish white, had changed to a black-brown color. When the liquid was removed at the end of the reaction and the remaining ethanol was completely evaporated, a magnesium-platinum metal composite structure was obtained.
[0142] The morphology of the raw magnesium microspheres and magnesium-platinum metal composite structure of Example 4 was characterized using optical microscopy, and the results are shown in FIG. 20, where FIG. 20a is a scanning electron micrograph of the raw magnesium microspheres and FIG. 20b is a scanning electron micrograph of the magnesium-platinum metal composite structure.
[0143] Comparing Figure 20a with Figure 20b, it can be seen that the surfaces of the microspheres in the magnesium-platinum metal composite structure are rough, and the rough surface is platinum that has adhered to the surfaces of the magnesium microspheres, and that platinum has been adhered to the surfaces of the magnesium microspheres through a reduction reaction, forming a magnesium-platinum metal composite structure.
[0144] Example 8: Magnesium-platinum metal composite structure The difference between Example 8 and Example 7 is that the particle size of the raw magnesium microspheres was about 500 μm, and the magnesium-platinum metal composite structure was prepared by the preparation method of Example 7.
[0145] Example 9: Magnesium-platinum metal composite structure A magnesium-platinum metal composite structure comprising a magnesium core structure and platinum particles bonded to the surface of the magnesium core structure, the core structure being rod-shaped. The rod-shaped magnesium-platinum metal composite structure was prepared as follows. A magnesium rod (diameter: 0.5 mm, length: 2 mm, commercially available) was placed in a 0.3% concentration of chloroplatinic acid ion (PtCl 6 2- After 1 minute of reaction, the rod-shaped magnesium-platinum metal composite structure was taken out and washed three times with absolute ethanol to remove unreacted ions on the surface. The prepared rod-shaped magnesium-platinum metal composite rod-shaped structure was placed in absolute ethanol, sealed, and stored. According to the principle of in situ exchange reduction, a magnesium-platinum metal composite structure was formed on the magnesium surface, and PtCl 6 2- reduces the platinum nanoparticles on the surface of the magnesium rod, resulting in a rod-shaped magnesium-platinum metal composite structure.
[0146] Figure 21 is the XRD diffraction pattern of the rod-shaped magnesium-platinum metal composite structure obtained by the preparation of Example 9, the vertical line on the abscissa axis of Figure 21 is the position and relative intensity of the standard XRD signal peak of magnesium monomer, the curve graph is the XRD signal spectrum of the rod-shaped magnesium-platinum metal composite structure, and the diamond label is the position of the XRD signal peak of platinum monomer. As can be seen from Figure 21, the XRD spectrum of the magnesium-platinum metal composite rod-shaped structure is consistent with the standard signal peak position of magnesium monomer for the signal of magnesium monomer, and the platinum signal peak appears in addition to the strong magnesium signal, which further proves that platinum nanoparticles have grown normally on the surface of the magnesium rod, and a rod-shaped magnesium-platinum metal composite structure has been obtained.
[0147] Example 10: Test of hydrogen generation rate from rod-shaped magnesium-platinum metal composite structure obtained in Example 9 In order to investigate the hydrogen generation ability of the rod-shaped magnesium-platinum metal composite structure, the rod-shaped magnesium-platinum metal composite structure obtained in Example 9 and a magnesium rod alone, both prepared to the same size, were placed in 50 mL of phosphate buffer, and the amount of hydrogen generated by the rod-shaped magnesium-platinum metal composite structure and the magnesium rod alone were quantitatively measured by gas chromatography at different time intervals.
[0148] The graph of the total amount of hydrogen generation is shown in Figure 22. As can be seen from the results in Figure 22, when the magnesium rod is immersed in the buffer solution, only a small amount of hydrogen is generated in the very early stage, but the rod-shaped magnesium-platinum metal composite structure can continue to generate a large amount of hydrogen for a longer period of time, and its hydrogen generation rate and total amount are much greater than those of a simple magnesium rod. This experimental result directly demonstrates that the magnesium-platinum metal composite structure described in this invention has excellent hydrogen generation ability and has the potential for further use in tumor treatment.
[0149] Example 11: Composite embolic agent 13 is a composite embolic agent consisting of the magnesium-platinum metal composite structure of Example 9 and iodine oil. By adjusting the length-to-diameter ratio of the rod-shaped metal composite structure, better fixation of the metal composite structure at the action site can be achieved, and the metal composite structure can avoid the occlusion of blood vessels of other normal tissues caused by the metal composite structure entering the blood circulation when using the composite embolic agent of magnesium-platinum metal composite rod-shaped structure and iodine oil.
[0150] Example 12: Aluminum-Gallium Metal Composite Structure An aluminum-gallium metal composite structure consisting of an aluminum core structure and gallium particles bound to the surface of the aluminum core structure was prepared as follows. At room temperature, 200 mg of aluminum powder (300 mesh, approximately 48 microns) was placed in a 4 mL centrifuge tube, 200 mg of liquid metal gallium was added dropwise, and magnetic stirring was performed for 10 minutes to prepare an aluminum-gallium metal composite structure by utilizing the strong fusion property of gallium to aluminum. After stirring, the tube was washed several times with absolute ethanol, sealed, and stored in absolute ethanol and left to stand by.
[0151] Example 13: Composite embolic agent The composite embolic agent is composed of the aluminum-gallium metal composite structure of Example 12 and iodine oil. The aluminum-gallium metal composite structure is mixed with iodine oil, and the aluminum-gallium metal composite structure is dispersed more uniformly in the iodine oil by ultrasonication. Aluminum metal reacts with water to form aluminum hydroxide, which can be used as an immune adjuvant to regulate the immune microenvironment at the tumor site and enhance the effect of immunotherapy.
[0152] Example 14: Alloy metal particle composite embolic agent The alloy metal particle composite embolic agent is composed of platinum-gold alloy metal particles and iodine oil, where the platinum-gold alloy metal particles are commercially purchased, and the alloy metal particles may be further doped with other ions having the function of providing trace elements.
[0153] For example, to obtain a composite embolic agent of alloy metal particles and iodine oil, the surface of platinum-gold alloy metal particles is exposed to metallic zinc, metallic iron, and metallic manganese.
[0154] Example 15: Large-sized metal microspheres, specifically magnesium microspheres, having a particle size distribution as shown in FIG. 23 and a particle size of about 350±45 microns are taken as an example.
[0155] Example 16: To explore the effect of hydrogen gas generation from the large-sized microspheres described in Example 15 in buffer solutions with different pH conditions. 20 mg of magnesium microspheres were placed in 4 mL of phosphate buffer solutions with different pH values, and the cumulative amount of hydrogen generated by the reaction of magnesium microspheres in buffer solutions with different concentrations was quantitatively measured in real time using a gas chromatograph.
[0156] Figure 24 shows the results of measuring hydrogen generation at pH for magnesium microspheres with a particle size of about 350±45μm. At pH=7.4, there was almost no hydrogen generation in the buffer solution, and at pH=6.4, hydrogen could be generated compared to the pH=7.4 condition, but the hydrogen yield was small and the hydrogen generation rate was slow. At pH=5.5, the cumulative amount of hydrogen generated by magnesium microspheres reached about 3.5 times that of pH=6.4 in a 350-second reaction, indicating that magnesium microspheres can generate hydrogen in a weakly acidic environment and that the hydrogen generation rate increases as the pH decreases. This indicates that magnesium microspheres with a large particle size can generate hydrogen in the slightly acidic physiological environment of tumors, which may be further applied to tumor hydrogen therapy.
[0157] Example 17: A composite embolic agent containing large-sized active metal microspheres composed of the large-sized magnesium microspheres (particle size of about 350±45 microns) described in Example 15 and an iodine oil embolic agent (commercially purchased product). The large-sized magnesium microspheres and iodine oil were mixed so that the mass ratio of magnesium microspheres to iodine oil was 10:100. A uniformly dispersed emulsion was obtained by ultrasonic treatment.
[0158] The magnesium-platinum composite structure can generate hydrogen in physiological solutions with neutral pH conditions, and the active metal microspheres can generate hydrogen in physiological solutions with weakly acidic pH conditions. All of these microspheres and the compatible embolic agents formed with iodine oil have the function of supplying hydrogen gas to enhance tumor embolization therapy.
[0159] Example 18: Magnesium microspheres with a particle size of about 175 μm were produced by ultrasonic atomization powder method. The obtained magnesium microspheres were observed under a microscope to observe their microscopic morphology and count their particle size distribution, the result of which is shown in Figure 25, the particle size range of the magnesium microspheres was about 174±19 μm, which indicates that the median particle size of the magnesium microspheres is about 174 μm.
[0160] The hydrogen release rate from 5 mg of magnesium microspheres of Example 18 was measured in citric acid-sodium citrate buffer at different pH values (pH 5.5, 6.4, 7.4). By determining the concentration of hydrogen released at different time points, the statistical results are shown in FIG. 26. The ordinate is the concentration of hydrogen, and the unit mM is millimoles per liter. The higher the amount of hydrogen released per unit time, the stronger the reaction of magnesium microspheres. This result shows that compared with neutral pH buffer (pH = 7.4), the amount of hydrogen released per unit time is higher in buffers with pH = 6.4 and pH = 5.5. That is, it shows that magnesium microspheres are easy to generate hydrogen in a weak acidic environment, which contributes to improving the microenvironment (5.5-6.5) at the tumor site and enhances the effect of embolization therapy.
[0161] Example 19: Use of magnesium microspheres from Example 18 for embolization therapy in a rabbit hepatoma model With the help of CT image guidance, VX2 hepatocellular carcinoma tissue was directly embedded in the left lobe of the liver, and an in situ rabbit hepatocellular carcinoma tumor model was obtained after 2 weeks. The left side of Figure 27 is the image detection after the establishment of the rabbit hepatocellular carcinoma model, which proves that the hepatocellular carcinoma model in the left lobe of the liver of the hormone rabbit has been established, and it can be observed that the size of the hepatocellular carcinoma focus in the left lobe of the liver of the hormone rabbit is 1.0-1.5 cm.
[0162] The hormonal rabbits were randomly divided into two groups and treated separately.
[0163] Example 19.1: The magnesium microspheres of Example 18 were implanted into rabbit hepatocellular carcinoma lesions according to the scheme of FIG. 8 for embolization therapy. Comparative Example 19.2: Control group, no treatment manipulation.
[0164] As a result of observing the blood vessels at the lesion site using the above method, as shown in the right diagram of FIG. 27, it was found that a part of the blood supply to the rabbit's liver was lost (compared with the left diagram, the original angiogram was shallower, indicating insufficient blood supply), which indicates that embolization of the hepatic artery was achieved by administering the 175 μm magnesium microspheres provided in Example 18 using the femoral artery interventional technique.
[0165] At the same time, an ultrasound examination was performed to detect gas echoes in the liver lesions, and the results are shown in Figure 28. Comparing the preoperative (left) and postoperative (right) images, the area embolized with magnesium microspheres had stronger signals, i.e., stronger gas echoes, indicating that the magnesium microspheres generated hydrogen at the embolization site, demonstrating that the magnesium microspheres generate hydrogen at the same time as embolization, and can exert the effects of hydrogen therapy.
[0166] On the 4th and 7th days after treatment, the therapeutic effect was evaluated by CT imaging in combination with iophorol contrast agent, and the results are shown in Figure 29 for CT imaging data at different times before and after treatment for Example 19.1 and Comparative Example 19.2. As a result, in Comparative Example 19.2, the tumor volume on the 4th day of administration increased 2.5 times compared to the tumor volume on the day before administration, and the tumor volume on the 7th day of administration increased 5.8 times compared to the tumor volume on the day before administration, and was evaluated as progressive disease (PD) according to the tumor response evaluation criteria (mRECIST). In Example 19.1, the tumor volume of the rabbit hepatocellular carcinoma lesion changed slowly, with the tumor volume on the 4th day being 2 times and the tumor volume on the 7th day being 1.8 times compared to the tumor volume on the day before administration, and was evaluated as effective remission based on the cancer therapeutic effect evaluation criteria (mRECIST).
[0167] Ki67 exists in the late G1, S, G2, and M phases of the cell cycle, but is not expressed in cells in the G0 phase, so the signal intensity of Ki67 responds to the proliferation activity of cells, and the stronger the Ki67 positive signal, the higher the proliferation activity of cells, the higher the malignancy, and the worse the patient's prognosis. By observing the Ki67 staining of frozen sections of tumor tissue and counting the Ki67 fluorescence intensity, it was found that the proliferation activity of the sample with control ratio 2 was much higher than that of Example 19.1. This indicates that the activity of rabbit hepatocellular carcinoma cells was reduced after embolization therapy with magnesium microspheres, that is, embolization therapy with magnesium microspheres can effectively inhibit hepatocellular carcinoma and may treat hepatocellular carcinoma.
[0168] Example 20: A manganese-platinum metal composite structure comprising a first metal, manganese, and a second metal, platinum, bonded to the surface of the manganese. A manganese-platinum metal composite structure was prepared using a displacement method as follows. At room temperature, 200 mg of manganese powder (1-5 μm) was dispersed in 10 mL of anhydrous ethanol solution and dissolved in sodium chloroplatinate (PtCl) with a mass fraction of 0.5% under magnetic stirring conditions. 6A manganese-platinum metal composite structure was prepared by dropping an anhydrous ethanol solution containing 1,0 ...
[0169] In the obtained manganese-platinum metal composite structure, due to the difference in active metals between manganese and the two metals platinum, the platinum nanoparticles attached to the manganese metal surface act as the positive electrode of the primary cell reaction, and manganese acts as the negative electrode of the primary cell reaction. Therefore, the manganese-platinum metal primary cell composite structure can spontaneously carry out the primary cell reaction in an aqueous solution and continuously generate hydrogen, thereby achieving the purpose of improving the tumor microenvironment and realizing hydrogen therapy.
[0170] The elemental analysis of the prepared manganese-platinum metal composite structure was performed using an X-ray diffraction apparatus. Figure 30 shows the X-ray diffraction spectrum of the manganese-platinum metal composite structure, in which a platinum signal appears in addition to the signal peak of metallic manganese, proving that metallic platinum was attached to the surface of the metallic manganese core by an oxidation-reduction reaction, and a metal composite structure was formed.
[0171] Example 21: Hydrogen generation efficiency experiment in vitro The manganese-platinum metal composite structure prepared in Example 20 was placed in a phosphate buffer solution, and the amount of hydrogen generated at different times was quantitatively detected using gas chromatography. FIG. 31 is a statistical graph of the amount of hydrogen generated by metal manganese and the manganese-platinum metal composite structure in a phosphate buffer solution at different times, and the results show that manganese cannot generate hydrogen stably and sustainably in a phosphate buffer solution. On the other hand, the manganese-platinum metal composite structure can generate hydrogen more stably and sustainably, and the total amount of hydrogen generated is high, and the cumulative amount of hydrogen generated after 72 hours of reaction is 10 times that of manganese. Therefore, the manganese-platinum metal composite structure with an active metal as a core structure is expected to be applied to hydrogen therapy compared to an inactive metal.
[0172] Example 22: Validation of manganese-platinum metal composite structures for tumor treatment in mice Using the manganese-platinum metal composite structure prepared in Example 20, the tumor microenvironment control ability and hydrogen generation ability were examined in a mouse subcutaneous colon cancer tumor model. First, a mouse subcutaneous colon cancer tumor model was established and 3 × 10 6 CT26 mouse colon cancer cells were inoculated into the right hindquarters of the mouse, and the subcutaneous colon cancer tumor volume of the mouse was approximately 150 mm. 3 At maturity, the mice were randomly divided into three groups.
[0173] Example 22.1: Control group, no treatment. Example 22.2: A suspension of metallic micron-sized manganese particles was injected intratumorally at 1.5 mg / particle. Example 22.3: A manganese-platinum metal composite structure suspension was injected into the tumor at a dose of 1.5 mg / unit. The manganese-platinum metal composite structure prepared by the method described in Example 20 was injected into the tumor of mice, and after treatment with different means, the tumor volume was measured every two days up to 1500 mm, which was regarded as the end point of monitoring. 3 The tumor growth was monitored until it became larger than the control group. As shown in FIG. 32, in Example 22.2, the tumor growth of the mouse was only slightly inhibited, and the difference from the control group was small. On the other hand, in Example 22.3, the tumor growth of the mouse was significantly inhibited. This shows that the manganese-platinum metal composite structure described in the present invention can be used for hydrogen therapy of tumors, and the effect is significantly improved compared to hydrogen therapy using micron-sized manganese particles.
[0174] Example 23: Retention at the lesion site Tumors were inoculated subcutaneously into mice, and tumor volumes were 60–80 mm 3When the tumor reached 40 mg / mL, 50 microliters of magnesium microsphere iodine oil composite embolic agent obtained in Example 1 was injected into the tumor in each mouse, and the mice were sacrificed at different time points and tumors were taken from the mice. The tumors were then excised with an aquaregia, and the Mg content in the tissue was measured by ICP-OES, and the intratumoral magnesium residual rate was calculated as magnesium residual rate = mass of magnesium in tumor / total dose used. Figure 33 shows the statistics of residual magnesium at different times in the tumor site of the mice after intratumoral injection of magnesium microsphere iodine oil composite embolic agent.
[0175] As a result, as shown in Figure 33, the magnesium microspheres can remain at the tumor site for a certain period of time (about 4 days), which shows that the composite embolic agent can remain at the lesion site for a long period of time, and has a long-term embolization effect and microenvironment regulation effect. With the extension of time, the content of magnesium microspheres gradually decreases and can be effectively metabolized, which shows that magnesium microspheres can be decomposed slowly, that is, magnesium microspheres can be decomposed and metabolized in the body, and the safety risk to the human body is low.
[0176] Example 24: Tumor site pH regulation Mice were inoculated with tumors subcutaneously until tumor volumes reached 100–150 mm 3 At the time when the pH reached 100, a pH electrode was inserted into the tumor to detect intratumoral pH. Then, 50 microliters of magnesium microsphere-iodine oil composite embolic agent prepared in Example 1, 40 mg / mL, was injected into the tumor of the mouse, and the change in intratumoral pH was monitored with the pH electrode.
[0177] FIG. 34 shows the change in intratumoral pH over time in mice in Example 24. Before the injection of the magnesium microsphere iodine oil composite embolic agent prepared in Example 1, the tumor site was in a weakly acidic pH environment, and the pH was maintained at about 6.7. After the magnesium microsphere iodine oil composite embolic agent was injected into the tumor, the intratumoral pH rose to about 7.6 and remained stable. This shows that the magnesium microsphere composite embolic agent prepared in Example 1 has the ability to adjust the acidic microenvironment in the tumor and improve the acidic environment at the tumor site. If the pH at the tumor site is low, it will play a role in promoting tumor progression, affect the effect of tumor treatment, form a suppressive immune microenvironment, and help the tumor to produce immune escape. The magnesium microsphere iodine oil composite embolic agent prepared in Example 1 can improve the acidic microenvironment at the tumor site and better inhibit tumor growth. Improving the acidic microenvironment at the tumor site helps to reduce the drug resistance of the tumor, so it also helps to improve the tumor treatment effect by combining other therapies such as chemotherapy, radiotherapy, and immunotherapy.
[0178] Example 25: Hydrogen generation efficiency of magnesium-platinum metal composite structures with different metal ratios A magnesium-platinum metal composite structure was obtained by subjecting a commercially available magnesium rod to a substitution reaction in an ethanol solution of sodium chloroplatinate at room temperature for about 1 minute. By changing the concentration of the sodium chloroplatinate solution, the substitution reaction occurred more sufficiently and quickly, so by changing the supply ratio, magnesium-platinum metal composite structures with different ratios could be obtained. Of these, the magnesium rod had a short diameter of about 0.5 mm and a long diameter of about 2 mm, and the size of the obtained magnesium-platinum metal composite structure was almost the same as that of the magnesium rod, with only a small amount of metallic platinum attached to the surface of the magnesium rod.
[0179] 4 mg of this magnesium-platinum metal composite structure was placed in 50 mL of phosphate buffer solution with a pH of 6.5, and the reaction was allowed to stand for 24 hours. The amount of hydrogen generated from the metal composite structures with different metal ratios was then detected by gas chromatography. FIG. 35 is a statistical graph showing the amount of hydrogen generated in the solutions of magnesium-platinum metal composite structures with different ratios for 24 hours (the mass fractions of metallic platinum relative to metallic magnesium in Example 25 are 0.2%, 0.5%, 2%, 5%, and 10%). The vertical axis indicates the total amount of hydrogen generated in the system in about 24 hours, and the horizontal axis indicates the mass fraction of platinum relative to the magnesium rod in the magnesium-platinum metal composite structure.
[0180] As can be seen from FIG. 35, as the mass fraction of platinum in the magnesium rod increases, the total amount of hydrogen generated in 24 hours gradually increases; when the mass fraction of platinum reaches 5%, the total amount of hydrogen generated in 24 hours tends to be stable; when the mass fraction of platinum in magnesium exceeds 5%, the total amount of hydrogen generated in 24 hours no longer undergoes significant changes. This shows that the ratio of the two metals in the magnesium-platinum metal composite structure affects the hydrogen generation efficiency in the magnesium-platinum metal composite structure. The mass fraction of platinum to magnesium can be in the range of 0.2% to 10%, preferably in the range of 0.2% to 5%. If the platinum content is too high, it will not contribute to a significant improvement in the hydrogen generation efficiency, but rather increase the content of metal elements in the body, increase the metabolic burden, and increase the production cost. Therefore, within the appropriate ratio range, it is possible to ensure the hydrogen generation efficiency, suppress the production cost, and further improve the safety to the human body.
[0181] Example 26: Hydrogen generation efficiency of manganese-platinum metal composite structures with different metal ratios Commercially available manganese powder (particle size approximately 2.5 μm) was placed in an ethanol solution of sodium chloroplatinate and subjected to a substitution reaction at room temperature for approximately 10 minutes to obtain a manganese-platinum metal composite structure, and manganese-platinum metal composite structures with different ratios were obtained by changing the concentration of the sodium chloroplatinate solution depending on the supply ratio. Among these, the particle size of the manganese powder was approximately 2.5 μm, and the particle size of the manganese powder after the attachment of metallic platinum was distributed from 2.5 to 5.5 μm.
[0182] 40 mg of this manganese-platinum metal composite structure was placed in 50 mL of a phosphate buffer solution with a pH of 6.5, and the reaction was closed for 24 hours. The amount of hydrogen generated from the metal composite structures with different metal ratios was then detected by gas chromatography. Figure 36 is a statistical graph showing the amount of hydrogen generated from the manganese-platinum metal composite structures with different ratios in the 24-hour solution of Example 25.2 (the mass fractions of platinum relative to manganese are 0, 1%, 2%, 5%, 10%, and 20%, respectively).
[0183] The vertical axis represents the total amount of hydrogen generated in the system in about 24 hours, and the horizontal axis represents the mass ratio of platinum powder to manganese powder in the manganese-platinum metal composite structure.
[0184] As can be seen from FIG. 36, as the mass ratio of platinum to micron-sized manganese particles increases, the amount of hydrogen generated increases.
[0185] The total amount of hydrogen generated in 24 hours gradually increases, and when the mass fraction of platinum reaches 10%, the total amount of hydrogen generated in 24 hours tends to stabilize, and when the mass fraction of platinum on manganese exceeds 10%, the total amount of hydrogen generated in 24 hours no longer changes significantly. This shows that the ratio of the two metals in the manganese-platinum metal composite structure affects the hydrogen generation efficiency in the manganese-platinum metal composite structure. The mass fraction of platinum to manganese can be in the range of 1% to 20%, preferably 1% to 10%. If the platinum content is too high, it will not contribute to a significant improvement in the hydrogen generation efficiency, but rather increase the content of metal elements in the body, increase the metabolic burden, and increase the production cost. Therefore, within the appropriate ratio range, it is possible to ensure the hydrogen generation efficiency, suppress the production cost, and further improve the safety to the human body.
[0186] Example 27: Hydrogen generation efficiency of other alloy metal microspheres When preparing magnesium-platinum alloy metal microspheres, the hydrogen generation efficiency gradually decreases as the particle size of magnesium-platinum alloy metal microspheres increases and the platinum content decreases. This is believed to be because platinum is less easily dispersed on the surface of the alloy metal structure microspheres as the platinum content decreases. Compared with the metal composite structure, the efficiency of the primary cell reaction occurring on the surface decreases, and the hydrogen generation rate slows down. However, the alloy metal microspheres still have the ability to generate hydrogen, which may lead to further applications in tumor embolization therapy.
[0187] To achieve better efficacy, we want to generate more hydrogen at the lesion site, but the amount of hydrogen that can dissolve in tissues and physiological environments is limited, so the demand for treatment can be met by changing the actual parameters used, such as the dosage and frequency of administration. Therefore, different sizes of metal microspheres, alloy metal microspheres, and metal composite structures can be used as components of hydrogen therapy in composite embolic agents to realize tumor therapy.
[0188] Apparently, the above embodiments are merely examples for clarity, not for limiting the embodiments.
[0189] While several embodiments of the present invention that are presently believed to be useful have been discussed in the foregoing disclosure with various examples, it should be understood that such details serve illustrative purposes only, and that the appended claims are not limited to the disclosed embodiments, but rather are intended to cover all modifications and equivalent combinations consistent with the substance and scope of the embodiments of the present application.
[0190] Similarly, it should be noted that the foregoing description of the embodiments of the present application sometimes groups together various features in a single embodiment, accompanying drawing, or description thereof in order to simplify the presentation of the disclosure of the present application and thus aid in the understanding of one or more embodiments of the present invention. However, this method of disclosure does not imply that more features than are recited in the claims are required for the subject matter of the present application. In fact, an embodiment may have fewer than all features of a single embodiment disclosed above.
[0191] In some embodiments, numbers are used to describe the number of components, attributes, and it should be understood that such numbers used in the description of the embodiments are modified in some instances by the modifiers "about," "approximately," or "generally." Unless otherwise specified, "about," "approximately," or "generally" indicate that ±variation in the stated numerical value is permitted. Thus, in some embodiments, the numerical parameters used in the specification and claims are approximations and may vary depending on the desired properties of the particular embodiment.
[0192] Finally, it should be understood that the embodiments described herein are merely used to explain the principles of the embodiments of the present application. Other variations may fall within the scope of the present application. Thus, by way of example, and not of limitation, alternative configurations of the embodiments of the present application may be considered consistent with the teachings of the present application. Thus, the embodiments of the present application are not limited to the embodiments expressly shown and described herein.
Claims
1. A composite embolic agent of active metal microspheres or nano-hydride based on iodine oil, comprising active metal microspheres or nano-hydride material and iodine oil, and the mass percentage of the active metal microspheres or nano-hydride material in the composite embolic agent is 0.1-10%.
2. 2. The composite embolic agent according to claim 1, wherein the particle size of said active metal microspheres is 0.1 to 20 microns.
3. The composite embolic agent according to claim 1, characterized in that the nano-hydride has a particle size of 5 to 200 nm.
4. 2. The composite embolic agent according to claim 1, wherein the active metal microspheres are prepared by an aerosolized powder method, i.e., by heating and melting an active metal ingot, followed by atomization and cooling to obtain the active metal microspheres.
5. 2. The composite embolic agent according to claim 1, characterized in that the nano-hydride material is prepared by liquid phase stripping method, i.e. ultrasonically dispersing metal hydride in stripping solvent and centrifuging to obtain the nano-hydride material.
6. 5. The composite embolic agent according to claim 4, wherein the active metal has a metal activity greater than that of hydrogen and includes one or more of magnesium, aluminum, zinc, gallium, iron, manganese and tin.
7. 6. The composite embolic agent according to claim 5, wherein the metal hydride is one or more of calcium hydride, magnesium hydride, lithium hydride, sodium hydride, potassium hydride, strontium hydride and cerium hydride.
8. 6. The composite embolic agent according to claim 5, wherein the stripping solvent is one or more of N-methylpyrrolidone, dimethylsulfoxide, polyethylene glycol 200, pyrrole and N,N-dimethylformamide.
9. A method for preparing the composite embolic agent according to any one of claims 1 to 8, comprising the steps of mixing iodine oil with active metal microspheres or nanohydrides and dispersing them uniformly to obtain the composite embolic agent.
10. The application of the composite embolic agent according to any one of claims 1 to 8 in the preparation of a therapeutic agent for embolization of liver cancer.
11. 2. The composite embolic agent according to claim 1, wherein the particle size of said active metal microspheres is 20 to 500 microns.
12. The composite embolic agent according to claim 1, characterized in that the nano-hydride has a particle size of 0.2 to 500 microns.
13. The active metal microspheres have a metal activity stronger than a hydrogen activity.
14. 14. The active metal microspheres according to claim 13, characterized in that the particle size of said active metal microspheres is 0.1 to 500 microns.
15. 15. The active metal microspheres according to claim 13 or 14, characterized in that the active metal microspheres are prepared from an active metal, the active metal being selected from at least one of magnesium, aluminum, zinc, gallium, iron, manganese and tin, and having a metal activity greater than the activity of hydrogen.
16. 16. The active metal microspheres according to any one of claims 13 to 15, characterized in that the active metal microspheres have a spherical shape, a porous structure, a sea urchin shape or a polyhedral structure.
17. A composite embolic agent comprising the active metal microspheres according to any one of claims 13 to 16.
18. The composite embolic agent according to claim 17, further comprising a dispersing agent.
19. 19. The composite embolic agent according to claim 18, wherein the mass ratio of the active metal microspheres to the dispersing agent is 0.1:100 to 50:
100.
20. 20. The composite embolic agent according to claim 18 or 19, characterized in that the dispersing agent is an organic phase.
21. The composite embolic agent according to any one of claims 18 to 20, characterized in that the dispersing agent is an oil phase.
22. 22. The composite embolic agent according to any one of claims 18 to 21, characterized in that the dispersing agent is selected from one or more of the following: iodine oil, poppy seed oil, soybean oil and olive oil.
23. The nano-hydride is characterized in that the nano-hydride has a particle size of 0.005 to 500 microns.
24. 24. The nanohydride of claim 23, wherein the nanohydride is selected from one or more of calcium hydride, magnesium hydride, lithium hydride, sodium hydride, potassium hydride, strontium hydride and cerium hydride.
25. A composite embolic agent comprising the nano-hydride according to claim 23 or 24.
26. 26. The composite embolic agent according to claim 25, further comprising a dispersing agent.
27. 27. The composite embolic agent according to claim 26, wherein the mass ratio of the nano-hydride to the dispersing agent is 0.1:100 to 50:
100.
28. 28. The composite embolic agent according to claim 26 or 27, characterized in that the dispersing agent is an organic phase.
29. The composite embolic agent according to any one of claims 26 to 28, characterized in that the dispersing agent is an oil phase.
30. 30. The composite embolic agent according to any one of claims 26 to 29, characterized in that the dispersing agent is selected from one or more of the following: iodine oil, poppy seed oil, soybean oil and olive oil.
31. An antitumor formulation comprising the active metal microspheres according to any one of claims 13 to 16.
32. A tumor preparation comprising the composite embolic agent according to any one of claims 17 to 22.
33. A tumor preparation comprising the nanohydride according to any one of claims 23 to 24.
34. A tumor preparation comprising the composite embolic agent according to any one of claims 25 to 30.
35. and a bonding layer bonded to a surface of the core structure, the core structure being a first metal and the bonding layer being a second metal.
36. 36. The metal composite structure according to claim 35, wherein the shape of the core structure is a sphere, a polyhedron, a porous structure, or a rod.
37. 36. The metal composite structure according to claim 35, wherein the metal activity of the first metal is stronger than the hydrogen activity.
38. The metal composite structure according to any one of claims 35 to 37, characterized in that the first metal is selected from one or more of magnesium, aluminum, zinc, gallium, iron, manganese and tin.
39. 39. The metal composite structure according to claim 35, wherein the second metal has a metal activity weaker than a hydrogen activity.
40. 40. The metal composite structure according to claim 35, wherein the second metal is selected from one or more of copper, silver, platinum and gold.
41. 41. The metal composite structure according to any one of claims 40 to 49, characterized in that the first metal is magnesium, the second metal is platinum, and the platinum has a mass fraction of magnesium of 0.2% to 10%.
42. 42. The metal composite structure of claim 41, wherein the first metal is magnesium and the second metal is platinum, the platinum having a magnesium mass fraction of 0.2% to 5%.
43. 41. The metal composite structure according to any one of claims 35 to 40, characterized in that the metal composite structure has a grain size of 0.1 to 500 microns.
44. 42. The metal composite structure according to any one of claims 35 to 41, characterized in that the grain size of the metal composite structure is uniformly distributed.
45. 19. A composite embolic agent comprising the metal composite structure according to claim 11 and a dispersing agent, the metal composite structure being dispersed in the dispersing agent.
46. 46. The composite embolic agent according to claim 45, wherein the metal composite structures are uniformly dispersed in the dispersing agent.
47. 46. The composite embolic agent according to claim 45, wherein a mass ratio of said metal composite structure to said dispersing agent is 0.1:100 to 50:
100.
48. 47. The composite embolic agent according to claim 45 or 46, characterized in that the dispersing agent is an organic phase.
49. The composite embolic agent according to claim 48, characterized in that the organic phase is an oil phase.
50. 50. The composite embolic agent according to claim 49, characterized in that the oil phase is selected from one or more of the following: iodine oil, poppy seed oil, soybean oil and olive oil.
51. A method for preparing a metal composite structure according to any one of claims 35 to 44, characterized in that it comprises a step of bonding the second metal to a surface of the first metal.
52. 52. The method for preparing a metal composite structure according to claim 51, characterized in that a physical or chemical method is used to bond the second metal to the surface of the first metal.
53. 53. A method for preparing a metal composite structure according to claim 52, characterized in that the chemical methods are selected from substitution methods.
54. 54. A method for preparing a metal composite structure according to claim 53, characterized in that the substitution process comprises subjecting the first metal to a solution containing higher valent ions of the second metal.
55. 55. A method for preparing a metal composite structure according to claim 54, characterized in that the solution of high valent ions of the second metal includes at least one of chloroaurate ions, chloroplatinate ions, copper ions, and silver ions.
56. 53. A method for preparing a metal composite structure according to claim 52, characterized in that the physical method is a mechanical stirring method or a vapor deposition method.
57. 57. The method for preparing a metal composite structure according to claim 56, characterized in that the mechanical stirring method comprises mixing and stirring the second metal in a solid state and the first metal in a liquid state.
58. 13. An alloy metal particle comprising at least two metals having different activities, the two metals having different activities being present in an alloy mixture.
59. 59. The alloy metal particle of claim 58, characterized in that the alloy metal particle comprises at least one active metal monomer and at least one inactive metal monomer, the active metal monomer being mixed with the inactive metal monomer in an alloyed state.
60. 60. The alloy metal particle of claim 59, wherein the active metal monomer has a metal activity greater than its hydrogen activity.
61. 60. The alloy metal particle of claim 59, wherein the active metal monomer is selected from one or more of magnesium, aluminum, zinc, gallium, iron, manganese and tin.
62. 60. The alloy metal particle of claim 59, wherein the inert metal monomer has a metal activity less than the activity of hydrogen.
63. 60. The alloy metal particle of claim 59, wherein the inert metal monomer is selected from one or more of copper, silver, platinum and gold.
64. 59. The alloy metal particle of claim 58, wherein the alloy metal particle size is between 0.1 and 500 microns.
65. 65. A composite embolic agent comprising the alloy metal particles according to any one of claims 58 to 64 and a dispersant, wherein the alloy metal particles are dispersed in the dispersant.
66. 66. The composite embolic agent according to any one of claims 65, characterized in that the alloying metal particles are uniformly dispersed in the dispersing agent.
67. 66. The composite embolic agent according to claim 65, characterized in that the dispersing agent is an organic phase.
68. 68. The composite embolic agent according to claim 67, characterized in that the organic phase is an oil phase.
69. 69. The composite embolic agent according to claim 68, characterized in that the oil phase is selected from one or more of the following: iodine oil, poppy seed oil, soybean oil and olive oil.
70. 66. The composite embolic agent according to claim 65, characterized in that the mass fraction of said alloying metal particles in said dispersion is 0.1%-50%.
71. A method for treating a tumor, comprising using the active metal microspheres according to any one of claims 13 to 16 for the treatment of a tumor.
72. A method for treating a tumor, comprising using the composite embolic agent according to any one of claims 17 to 22 for tumor embolization therapy.
73. A method for treating a tumor, comprising using the nanohydride according to any one of claims 23 to 24 for the treatment of a tumor.
74. A method for treating a tumor, comprising using the composite embolic agent according to any one of claims 25 to 30 for treating a tumor.
75. A method for treating a tumor, comprising using the composite embolic agent according to any one of claims 45 to 50 for tumor embolization therapy.
76. A method for treating a tumor, comprising using the composite embolic agent according to any one of claims 65 to 70 for tumor embolization therapy.
Citation Information
Patent Citations
Mesoporous silica coated micron magnesium ball core-shell particles and preparation method thereof
CN109498593A
Multifunctional liquid metal embolizing agent as well as preparation and application thereof
CN111514368A
Thermotherapeutic suppository and its use method
CN1380106A
Introduced suppository and its application method
CN1381280A
